Thomas J. Polascik, MD
Director, Society of Urologic Oncology Program
Department / Division
Surgery /
Urology
Address
DUMC 2804
Durham, NC 27710
Appointment Telephone
919-684-2446
Office Telephone
919-684-4946
Fax Telephone
919-684-5220
- MD, University of Chicago Pritzker School of Medicine (Illinois), 1991
- General Surgery, Johns Hopkins Hospital (Maryland), 1991-1993
- Urology, James Buchanan Brady Urological Institute, Johns Hopkins Hospital (Maryland), 1993-1997
- Urologic Oncology, Johns Hopkins Hospital (Maryland), 1997-1998
- Fellow, American College of Surgeons
Clinical Interests
Robotic nerve-sparing prostate surgery; nerve-sparing focal therapy (cryosurgery, NanoKnife, hemiablation) for prostate cancer; minimally invasive (robotic, laparoscopic, cryotherapy) surgery for kidney tumors; urologic oncology
Research Interests
Prostate cancer imaging
Focal therapy of prostate cancer
Prostate cancer outcomes
Kidney cancer outcomes
Minimally invasive surgery
Nerve sparing cryotherapy
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Galil Medical
Representative Publications
Abern MR, Tsivian M, Polascik TJ. Focal Therapy of Prostate Cancer: Evidence-based Analysis for Modern Selection Criteria. Curr Urol Rep. 2012 Feb 2.
(2012)
Abstract
Stewart SB, Bañez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J Urol. 2012 Jan;187(1):103-8.
(2012)
Abstract
Tsivian M, Kim CY, Caso JR, Rosenberg MD, Nelson RC, Polascik TJ. Contrast Enhancement on Computed Tomography After Renal Cryoablation: An Evidence of Treatment Failure? J Endourol. 2012 Jan 4.
(2012)
Abstract
Tsivian M, Polascik TJ. Prostate cancer: Ideal candidates for focal therapy. Nat Rev Urol. 2012 Jan;9(1):12-3.
(2012)
Abstract
Tsivian M, Qi P, Kimura M, Chen VH, Chen SH, Gan TJ, Polascik TJ. The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. Urology. 2012 Jan;79(1):32-6.
(2012)
Abstract
Wattson DA, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MH, Salenius SA, D'Amico AV. The Number of High-Risk Factors and the Risk of Prostate Cancer-Specific Mortality After Brachytherapy: Implications for Treatment Selection. Int J Radiat Oncol Biol Phys. 2012 Jan 31.
(2012)
Abstract
Zhai L, Polascik TJ, Foo WC, Rosenzweig S, Palmeri ML, Madden J, Nightingale KR. Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration. Ultrasound Med Biol. 2012 Jan;38(1):50-61.
(2012)
Abstract
Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, Villers A, . Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int. 2011 Nov 11.
(2011)
Abstract
Baust JM, Klossner DP, Robilotto A, Vanbuskirk RG, Gage AA, Mouraviev V, Polascik TJ, Baust JG. Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis. BJU Int. 2011 Aug 26.
(2011)
Abstract
Caso JR, Tsivian M, Mouraviev V, Kimura M, Polascik TJ. Complications and postoperative events after cryosurgery for prostate cancer. BJU Int. 2011 Aug 22.
(2011)
Abstract
Cotter SE, Chen MH, Moul JW, Lee WR, Koontz BF, Anscher MS, Robertson CN, Walther PJ, Polascik TJ, D'Amico AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011 Sep 1;117(17):3925-32.
(2011)
Abstract
Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT 4th, Yan S, Dewhirst M, Kunnumakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila). 2011 Oct;4(10):1590-8.
(2011)
Abstract
Kimura M, Bañez LL, Gerber L, Qi J, Tsivian M, Freedland SJ, Satoh T, Polascik TJ, Baba S, Moul JW. Association between Preoperative Erectile Dysfunction and Prostate Cancer Features-An Analysis from the Duke Prostate Center Database. J Sex Med. 2011 Dec 21.
(2011)
Abstract
Kimura M, Bañez LL, Schroeck FR, Gerber L, Qi J, Satoh T, Baba S, Robertson CN, Walther PJ, Donatucci CF, Moul JW, Polascik TJ. Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med. 2011 Oct;8(10):2935-43.
(2011)
Abstract
Kimura M, Donatucci CF, Tsivian M, Caso JR, Moreira DM, Mouraviev V, Satoh T, Baba S, Polascik TJ. On-demand use of erectile aids in men with preoperative erectile dysfunction treated by whole gland prostate cryoablation. Int J Impot Res. 2011 Mar-Apr;23(2):49-55.
(2011)
Abstract
Kimura M, Yan H, Rabbani Z, Satoh T, Baba S, Yin FF, Polascik TJ, Donatucci CF, Vujaskovic Z, Koontz BF. Radiation-induced erectile dysfunction using prostate-confined modern radiotherapy in a rat model. J Sex Med. 2011 Aug;8(8):2215-26.
(2011)
Abstract
Matvey T, Polascik TJ. Editorial comment. Urology. 2011 May;77(5):1152-3; author reply 1153-4.
(2011)
Abstract
Mouraviev V, Kimura M, Venkatraman T, Tsivian M, Mouravieva V, Batinic-Haberle I, Polascik TJ, Wang H, Lascola C. Mn-Porphyrins as Novel Molecular MRI Contrast Agents. J Endourol. 2011 Nov 3.
(2011)
Abstract
Mouraviev V, Polascik TJ. New Frontiers in Imaging and Focal Therapy: Highlights From the Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer, February 24-27, 2010, Washington, DC. Rev Urol. 2011;13(2):104-11.
(2011)
Abstract
Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int. 2011 Oct;108(7):1074-85.
(2011)
Abstract
Rosenberg MD, Kim CY, Tsivian M, Suberlak MN, Sopko DR, Polascik TJ, Nelson RC. Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol. 2011 Apr;196(4):935-9.
(2011)
Abstract
Santucci KL, Snyder KK, Baust JM, Van Buskirk RG, Mouraviev V, Polascik TJ, Gage AA, Baust JG. Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. Prostate Cancer Prostatic Dis. 2011 Jun;14(2):97-104.
(2011)
Abstract
Tsivian M, Caso J, Kimura M, Polascik TJ. Renal function outcomes after laparoscopic renal cryoablation. J Endourol. 2011 Aug;25(8):1287-91.
(2011)
Abstract
Tsivian M, Caso JR, Kimura M, Polascik TJ. Renal tumors in solid organ recipients: Clinical and pathologic features. Urol Oncol. 2011 Jun 28.
(2011)
Abstract
Tsivian M, Moreira DM, Caso JR, Mouraviev V, Polascik TJ. Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol. 2011 May 20;29(15):2027-31.
(2011)
Abstract
Tsivian M, Polascik TJ. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int. 2011 Aug;108(3):371.
(2011)
Abstract
Van Poppel H, Becker F, Cadeddu JA, Gill IS, Janetschek G, Jewett MA, Laguna MP, Marberger M, Montorsi F, Polascik TJ, Ukimura O, Zhu G. Treatment of localised renal cell carcinoma. Eur Urol. 2011 Oct;60(4):662-72.
(2011)
Abstract
Baust JG, Klossner DP, Vanbuskirk RG, Gage AA, Mouraviev V, Polascik TJ, Baust JM. Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):151-61.
(2010)
Abstract
Caire AA, Sun L, Lack BD, Lum K, Tang P, Stackhouse DA, Robertson CN, Mouraviev V, Polascik TJ, Albala DM, Moul JW. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer Prostatic Dis. 2010 Sep;13(3):248-51.
(2010)
Abstract
Caire AA, Sun L, Polascik TJ, Albala DM, Moul JW. Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. BJU Int. 2010 Oct;106(8):1157-60.
(2010)
Abstract
Caire AA, Sun L, Robertson CN, Polascik TJ, Maloney KE, George DJ, Price MM, Stackhouse DA, Lack BD, Albala DM, Moul JW. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology. 2010 May;75(5):1122-7.
(2010)
Abstract
Caso JR, Mouraviev V, Tsivian M, Polascik TJ, Moul JW. Prostate cancer: an evolving paradigm. J Endourol. 2010 May;24(5):805-9.
(2010)
Abstract
Caso JR, Tsivian M, Mouraviev V, Polascik TJ, Moul JW. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU Int. 2010 Dec;106(11):1623-7.
(2010)
Abstract
Caso JR, Tsivian M, Mouraviev V, Polascik TJ. Predicting biopsy-proven prostate cancer recurrence following cryosurgery. Urol Oncol. 2010 Sep 6.
(2010)
Abstract
Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010 Apr 15;116(8):1887-92.
(2010)
Abstract
D'Amico AV, Chen MH, Sun L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int. 2010 Dec;106(11):1618-22.
(2010)
Abstract
Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010 Jul;58(1):57-64.
(2010)
Abstract
Kimura M, Baba S, Polascik TJ. Minimally invasive surgery using ablative modalities for the localized renal mass. Int J Urol. 2010 Mar;17(3):215-27.
(2010)
Abstract
Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010 Jan;105(2):191-201.
(2010)
Abstract
Kimura M, Mouraviev V, Tsivian M, Moreira DM, Mayes JM, Polascik TJ. Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. Urology. 2010 Nov;76(5):1258-65.
(2010)
Abstract
Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Caso J, Satoh T, Baba S, Vujaskovic Z, Baust JM, Baust JG, Polascik TJ. Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology. 2010 Sep;76(3):764.e14-20.
(2010)
Abstract
Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Vujaskovic Z, Satoh T, Baba S, Baust JM, Baust JG, Polascik TJ. Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density. Cryobiology. 2010 Aug;61(1):148-54.
(2010)
Abstract
Mouraviev V, Johansen TE, Polascik TJ. Contemporary results of focal therapy for prostate cancer using cryoablation. J Endourol. 2010 May;24(5):827-34.
(2010)
Abstract
Tang P, Sun L, Uhlman MA, Polascik TJ, Freedland SJ, Moul JW. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer. 2010 Oct 15;116(20):4711-7.
(2010)
Abstract
Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol. 2010 Mar;183(3):946-50.
(2010)
Abstract
Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW. Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men. Urology. 2010 Nov;76(5):1058-62.
(2010)
Abstract
Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Moul JW. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU Int. 2010 Nov 2.
(2010)
Abstract
Tsivian M, Chen VH, Kim CY, Zilberman DE, Mouraviev V, Nelson RC, Albala DM, Polascik TJ. Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center. Eur Urol. 2010 Jul;58(1):142-7.
(2010)
Abstract
Tsivian M, Hruza M, Mouraviev V, Rassweiler J, Polascik TJ. Prostate biopsy in selecting candidates for hemiablative focal therapy. J Endourol. 2010 May;24(5):849-53.
(2010)
Abstract
Tsivian M, Lyne JC, Mayes JM, Mouraviev V, Kimura M, Polascik TJ. Tumor size and endophytic growth pattern affect recurrence rates after laparoscopic renal cryoablation. Urology. 2010 Feb;75(2):307-10.
(2010)
Abstract
Tsivian M, Moreira DM, Caso JR, Mouraviev V, Madden JF, Bratslavsky G, Robertson CN, Albala DM, Polascik TJ. Predicting occult multifocality of renal cell carcinoma. Eur Urol. 2010 Jul;58(1):118-26.
(2010)
Abstract
Tsivian M, Moreira DM, Sun L, Mouraviev V, Kimura M, Moul JW, Polascik TJ. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urol Oncol. 2010 Jan 5.
(2010)
Abstract
Tsivian M, Mouraviev V, Albala DM, Caso JR, Robertson CN, Madden JF, Polascik TJ. Clinical predictors of renal mass pathological features. BJU Int. 2010 Nov 5.
(2010)
Abstract
Tsivian M, Polascik TJ. Editorial comment. Urology. 2010 Sep;76(3):687; discussion 687-8.
(2010)
Abstract
Tsivian M, Polascik TJ. Focal cryotherapy for prostate cancer. Curr Urol Rep. 2010 May;11(3):147-51.
(2010)
Abstract
Tsivian M, Polascik TJ. Recent advances in focal therapy of prostate and kidney cancer. F1000 Med Rep. 2010;2.
(2010)
Abstract
Tsivian M, Wright T, Price M, Mouraviev V, Madden JF, Kimura M, Wong T, Polascik TJ. 111-In-capromab pendetide imaging using hybrid-gamma camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer. Urol Oncol. 2010 Feb 27.
(2010)
Abstract
Uhlman MA, Sun L, Stackhouse DA, Caire AA, Polascik TJ, Robertson CN, Madden J, Vollmer R, Albala DM, Moul JW. Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology. 2010 Feb;75(2):460-6.
(2010)
Abstract
Uhlman MA, Sun L, Stackhouse DA, Polascik TJ, Mouraviev V, Robertson CN, Albala DM, Moul JW. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol. 2010 Mar;183(3):997-1001.
(2010)
Abstract
Zhai L, Madden J, Foo WC, Mouraviev V, Polascik TJ, Palmeri ML, Nightingale KR. Characterizing stiffness of human prostates using acoustic radiation force. Ultrason Imaging. 2010 Oct;32(4):201-13.
(2010)
Abstract
Zhai L, Madden J, Foo WC, Palmeri ML, Mouraviev V, Polascik TJ, Nightingale KR. Acoustic radiation force impulse imaging of human prostates ex vivo. Ultrasound Med Biol. 2010 Apr;36(4):576-88.
(2010)
Abstract
Caire AA, Sun L, Ode O, Stackhouse DA, Maloney K, Donatucci C, Mouraviev V, Polascik TJ, Robertson CN, Albala DM, Moul JW. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology. 2009 Sep;74(3):643-7.
(2009)
Abstract
Chen VH, Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technol Cancer Res Treat. 2009 Apr;8(2):99-104.
(2009)
Abstract
D'Alonzo RC, Gan TJ, Moul JW, Albala DM, Polascik TJ, Robertson CN, Sun L, Dahm P, Habib AS. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. J Clin Anesth. 2009 Aug;21(5):322-8.
(2009)
Abstract
Habib AS, Polascik TJ, Weizer AZ, White WD, Moul JW, ElGasim MA, Gan TJ. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesth Analg. 2009 Jun;108(6):1950-3.
(2009)
Abstract
Kimura M, Tsivian M, Mouraviev V, Mayes JM, Price MM, Bannister MC, Madden JF, Wong TZ, Polascik TJ. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. Int J Urol. 2009 Dec;16(12):971-5.
(2009)
Abstract
Mayes JM, Mouraviev V, Sun L, Tsivian M, Madden JF, Polascik TJ. Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol. 2009 May 16.
(2009)
Abstract
Mayes JM, Mouraviev V, Tsivian M, Krupski TL, Donatucci CF, Polascik TJ. Concordance in the perception of couples recovering from primary surgical treatment of prostate cancer. Int J Impot Res. 2009 Jul-Aug;21(4):253-60.
(2009)
Abstract
Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ. Prostate cancer: the new landscape. Curr Opin Urol. 2009 Mar;19(2):154-60.
(2009)
Abstract
Mouraviev V, Madden JF, Broadwater G, Mayes JM, Burchette JL, Schneider F, Smith J, Tsivian M, Wong T, Polascik TJ. Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol. 2009 Sep;182(3):938-47.
(2009)
Abstract
Mouraviev V, Mayes JM, Polascik TJ. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol. 2009 Apr;6(4):205-15.
(2009)
Abstract
Polascik TJ, Mayes JM, Mouraviev V. Nerve-sparing focal cryoablation of prostate cancer. Curr Opin Urol. 2009 Mar;19(2):182-7.
(2009)
Abstract
Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW, Mouraviev V. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. 2009 May 15;115(10):2104-10.
(2009)
Abstract
Polascik TJ, Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology. 2009 Oct;74(4):726-30.
(2009)
Abstract
Polascik TJ. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther. 2009;3:27-40.
(2009)
Abstract
Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW. Factors predicting prostatic biopsy Gleason sum under grading. J Urol. 2009 Jul;182(1):118-22; discussion 123-4.
(2009)
Abstract
Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol. 2009 Nov;182(5):2242-8.
(2009)
Abstract
Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int. 2009 Oct 10.
(2009)
Abstract
Tsivian M, Mayes JM, Krupski TL, Mouraviev V, Donatucci CF, Polascik TJ. Altered male physiologic function after surgery for prostate cancer: couple perspective. Int Braz J Urol. 2009 Nov-Dec;35(6):673-82.
(2009)
Abstract
Tsivian M, Sun L, Mouraviev V, Madden JF, Mayes JM, Moul JW, Polascik TJ. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology. 2009 Nov;74(5):1090-3.
(2009)
Abstract
Chen VH, Mayes JM, Madden JF, Stein AJ, Mouraviev V, Polascik TJ. The effect of cryoablation on the histologic interpretation of intraoperative biopsy of small clear cell renal carcinoma and renal oncocytoma. J Endourol. 2008 Aug;22(8):1617-21.
(2008)
Abstract
Chen VH, Mayes JM, Mouraviev V, Polascik TJ. Urothelial sloughing with obstruction after laparoscopic cryoablation of small renal carcinoma in solitary kidney. Urology. 2008 Sep;72(3):716.e1-2.
(2008)
Abstract
Demark-Wahnefried W, George SL, Switzer BR, Snyder DC, Madden JF, Polascik TJ, Ruffin MT 4th, Vollmer RT. Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials. 2008;5(3):262-72.
(2008)
Abstract
Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87.
(2008)
Abstract
Habib AS, White WD, El Gasim MA, Saleh G, Polascik TJ, Moul JW, Gan TJ. Transdermal nicotine for analgesia after radical retropubic prostatectomy. Anesth Analg. 2008 Sep;107(3):999-1004.
(2008)
Abstract
Isariyawongse BK, Sun L, Bañez LL, Robertson C, Polascik TJ, Maloney K, Donatucci C, Albala D, Mouraviev V, Madden JF, Moul JW. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology. 2008 Oct;72(4):882-6.
(2008)
Abstract
Koontz BF, Mouraviev V, Johnson JL, Mayes J, Chen SH, Wong TZ, Anscher MS, Sun L, Moul J, Polascik TJ. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):358-61.
(2008)
Abstract
Mayes JM, Mouraviev V, Polascik TJ. Impact of a cryotherapy training workshop on the adoption and utilization of cryotherapy in the community setting. Can J Urol. 2008 Aug;15(4):4147-52.
(2008)
Abstract
Mayes JM, Mouraviev V, Sun L, Madden JF, Polascik TJ. WITHDRAWN: Can the conventional sextant prostate biopsy reliably diagnose unilateral prostate cancer in low-risk, localized, prostate cancer? Prostate Cancer Prostatic Dis. 2008 May 13.
(2008)
Abstract
Megwalu II, Ferguson GG, Wei JT, Mouraviev V, Polascik TJ, Taneja S, Black L, Andriole GL, Kibel AS. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int. 2008 Aug 5;102(5):546-50.
(2008)
Abstract
Mouraviev V, Broadwater G, Sun L, Mayes JM, Moul JW, Polascik TJ. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? Urology. 2008 Jun;71(6):1020-3.
(2008)
Abstract
Polascik TJ, Mayes JM, Mouraviev V. From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer. Oncology (Williston Park). 2008 Jul;22(8):900-6; discussion 906-7, 914.
(2008)
Abstract
Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008 Sep 15;68(13):1380-6.
(2008)
Abstract
Polascik TJ, Mouraviev V. Focal therapy for prostate cancer. Curr Opin Urol. 2008 May;18(3):269-74.
(2008)
Abstract
Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag. 2008 Feb;4(1):261-8.
(2008)
Abstract
Polascik TJ. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis. 2008;11(1):13-9.
(2008)
Abstract
Schroeck FR, Donatucci CF, Smathers EC, Sun L, Albala DM, Polascik TJ, Moul JW, Krupski TL. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008 Nov 15;113(10):2687-94.
(2008)
Abstract
Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ, Robertson CN, Tewari AK, Moul JW. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008 Oct;54(4):785-93.
(2008)
Abstract
Schroeck FR, Sun L, Freedland SJ, Albala DM, Mouraviev V, Polascik TJ, Moul JW. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU Int. 2008 Jul;102(1):28-32.
(2008)
Abstract
Stein AJ, Mayes JM, Mouraviev V, Chen VH, Nelson RC, Polascik TJ. Persistent contrast enhancement several months after laparoscopic cryoablation of the small renal mass may not indicate recurrent tumor. J Endourol. 2008 Nov;22(11):2433-9.
(2008)
Abstract
Chen SH, Mouraviev V, Mayes JM, Polascik TJ. Prostatic abscess as a delayed complication following cryosurgery for primary prostate cancer. Can J Urol. 2007 Aug;14(4):3646-8.
(2007)
Abstract
Chen SH, Mouraviev V, Raj GV, Marguet CG, Polascik TJ. Ureteropelvic junction obliteration resulting in nephrectomy after radiofrequency ablation of small renal cell carcinoma. Urology. 2007 May;69(5):982.e3-5.
(2007)
Abstract
Marguet C, Raj GV, Brashears JH, Anscher MS, Ludwig K, Mouraviev V, Robertson CN, Polascik TJ. Rectourethral fistula after combination radiotherapy for prostate cancer. Urology. 2007 May;69(5):898-901.
(2007)
Abstract
Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, Polascik TJ, Robertson CN, Dahm P, Anscher MS, Mouraviev V, Pappas PA, Albala DM. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol. 2007 Feb;177(2):499-503; discussion 503-4.
(2007)
Abstract
Mouraviev V, Joniau S, Van Poppel H, Polascik TJ. Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Eur Urol. 2007 Feb;51(2):328-36.
(2007)
Abstract
Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ. Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat. 2007 Apr;6(2):91-5.
(2007)
Abstract
Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007 Aug 15;110(4):906-10.
(2007)
Abstract
Mouraviev V, Nosnik I, Robertson C, Albala D, Walther P, Polascik TJ. Comparative financial analysis of minimally invasive surgery to open surgery for small renal tumours < or =3.5 cm: a single institutional experience. Eur Urol. 2007 Mar;51(3):715-20; discussion 720-1.
(2007)
Abstract
Mouraviev V, Nosnik I, Sun L, Robertson CN, Walther P, Albala D, Moul JW, Polascik TJ. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007 Feb;69(2):311-4.
(2007)
Abstract
Mouraviev V, Sun L, Madden JF, Mayes JM, Moul JW, Polascik TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007 Dec;70(6):1141-5.
(2007)
Abstract
Polascik TJ, Mouraviev V. The rise of ablative technologies for treating the small renal mass. Eur Urol. 2007 Sep;52(3):636-8.
(2007)
Abstract
Polascik TJ, Nosnik I, Mayes JM, Mouraviev V. Short Term Clinical Outcome after Laparoscopic Cryoablation of the Renal Tumor < or = 3.5 cm. Technol Cancer Res Treat. 2007 Dec;6(6):621-4.
(2007)
Abstract
Polascik TJ, Nosnik I, Mayes JM, Mouraviev V. Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology. 2007 Jul;70(1):117-21.
(2007)
Abstract
Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 2007 Jan 22.
(2007)
Abstract
Tseng TY, Cancel QV, Fesperman SF, Kuebler HR, Sun L, Robertson CN, Polascik TJ, Moul JW, Vieweg J, Albala DM, Dahm P. The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. J Urol. 2007 Apr;177(4):1318-23.
(2007)
Abstract
Auge BK, Santa-Cruz RW, Polascik TJ. Effect of freeze time during renal cryoablation: a swine model. J Endourol. 2006 Dec;20(12):1101-5.
(2006)
Abstract
Mouraviev V, Evans B, Polascik TJ. Salvage prostate cryoablation after primary interstitial brachytherapy failure: a feasible approach. Prostate Cancer Prostatic Dis. 2006;9(1):99-101.
(2006)
Abstract
Mouraviev V, Polascik TJ. Editorial comment. J Urol. 2006 Jun;175(6):2169.
(2006)
Abstract
Mouraviev V, Polascik TJ. Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol. 2006 May;16(3):152-6.
(2006)
Abstract
Nosnik IP, Mouraviev V, Nelson R, Polascik TJ. Multiple nephron-sparing procedures in solitary kidney with recurrent, metachronous, nonfamilial renal cell carcinoma. Urology. 2006 Dec;68(6):1343.e1-3.
(2006)
Abstract
Raj GV, Yowell C, Madden JF, Nosnik I, Mouraviev V, Polascik TJ. Malignant cystic nephroma. Can J Urol. 2006 Dec;13(6):3348-50.
(2006)
Abstract
Wiygul JB, Lallas C, Silverstein A, Polascik TJ. Ovarian hyperstimulation causing ureteral obstruction in a pregnant woman. Urology. 2006 May;67(5):1085.e5-6.
(2006)
Abstract
Brashears JH 3rd, Raj GV, Crisci A, Young MD, Dylewski D, Nelson R, Madden JF, Polascik TJ. Renal cryoablation and radio frequency ablation: an evaluation of worst case scenarios in a porcine model. J Urol. 2005 Jun;173(6):2160-5.
(2005)
Abstract
Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, Barkley CS, Bilhartz DL, McWhorter LT, Lacerna LV. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 2005 Nov;66(5):1054-9.
(2005)
Abstract
Raj GV, Brashears JH, Anand A, Paulson DF, Polascik TJ. Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy? Urology. 2005 Feb;65(2):332-6.
(2005)
Abstract
Weizer AZ, Raj GV, O'Connell M, Robertson CN, Nelson RC, Polascik TJ. Complications after percutaneous radiofrequency ablation of renal tumors. Urology. 2005 Dec;66(6):1176-80.
(2005)
Abstract
Wiygul JB, Evans BR, Peterson BL, Polascik TJ, Walther PJ, Robertson CN, Albala DM, Demark-Wahnefried W. Supplement use among men with prostate cancer. Urology. 2005 Jul;66(1):161-6.
(2005)
Abstract
Wong TZ, Turkington TG, Polascik TJ, Coleman RE. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. 2005 Feb;184(2):676-80.
(2005)
Abstract
Demark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, Vollmer RT. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology. 2004 May;63(5):900-4.
(2004)
Abstract
Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9.
(2004)
Abstract
Raj GV, Ellington KS, Polascik TJ. Autoimmune testicular vasculitis. Urology. 2003 May;61(5):1035.
(2003)
Abstract
Raj GV, Reddan DJ, Hoey MF, Hoey MB, Polascik TJ. Management of small renal tumors with radiofrequency ablation. Urology. 2003 Jan;61(1):23-9.
(2003)
Abstract
Santa-Cruz RW, Auge BK, Lallas CD, Preminger GM, Polascik TJ. Use of bipolar laparoscopic forceps to occlude and transect the retroperitoneal vasculature: a porcine model. J Endourol. 2003 Apr;17(3):181-5.
(2003)
Abstract
Munver R, Threatt CB, Delvecchio FC, Preminger GM, Polascik TJ. Hypertonic saline-augmented radiofrequency ablation of the VX-2 tumor implanted in the rabbit kidney: a short-term survival pilot study. Urology. 2002 Jul;60(1):170-5.
(2002)
Abstract
Polascik TJ and Marshall FF: Surgery for neoplastic involvement of the renal vein and inferior vena cava. In: Management of Urologic Malignancies. Eds. Hamdy FC, Basler JW, Neal DE and Catalona WJ. Churchill Livingstone, London, 2002
Polascik TJ and Marshall FF: Partial nephrectomy. In: Management of Urologic Malignancies. Eds. Hamdy FC, Basler JW, Neal DE and Catalona WJ. Churchill Lovingstone, London, 2002.
(2002)
Polascik TJ, Bostwick DG, Cairns P. Molecular genetics and histopathologic features of adult distal nephron tumors. Urology. 2002 Dec;60(6):941-6.
(2002)
Abstract
Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002 Jul;168(1):273-80.
(2002)
Abstract
Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002 Feb 15;94(4):987-96.
(2002)
Abstract
DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, Polascik TJ, Price DT. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001 Jan 1;61(1):110-7.
(2001)
Abstract
Demark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, Walther PJ, Gannon M, Vollmer RT. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology. 2001 Jul;58(1):47-52.
(2001)
Abstract
Reddan DN, Raj GV, Polascik TJ. Management of small renal tumors: an overview. Am J Med. 2001 May;110(7):558-62.
(2001)
Abstract
Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. 2001 Mar;7(1):27-37.
(2001)
Abstract
Haseman MK, Rosenthal SA, Polascik TJ. Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm. 2000 Apr;15(2):131-40.
(2000)
Abstract
Munver R, Donehower RC, Kronz JD, Polascik TJ. HIV infection presenting as an unusually large pure yolk sac tumor of the testis. J Urol. 2000 Nov;164(5):1653-4.
(2000)
Abstract
Wolf JS Jr, Marcovich R, Gill IS, Sung GT, Kavoussi LR, Clayman RV, McDougall EM, Shalhav A, Dunn MD, Afane JS, Moore RG, Parra RO, Winfield HN, Sosa RE, Chen RN, Moran ME, Nakada SY, Hamilton BD, Albala DM, Koleski F, Das S, Adams JB, Polascik TJ. Survey of neuromuscular injuries to the patient and surgeon during urologic laparoscopic surgery. Urology. 2000 Jun;55(6):831-6.
(2000)
Abstract
Polascik TJ, Hamper U, Lee BR, Dai Y, Hilton J, Magee CA, Crone JK, Shue MJ, Ferrell M, Trapanotto V, Adiletta M, Partin AW. Ablation of renal tumors in a rabbit model with interstitial saline-augmented radiofrequency energy: preliminary report of a new technology. Urology. 1999 Mar;53(3):465-72; discussion 470-2.
(1999)
Abstract
Polascik TJ, Manyak MJ, Haseman MK, Gurganus RT, Rogers B, Maguire RT, Partin AW. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer. 1999 Apr 1;85(7):1586-92.
(1999)
Abstract
Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol. 1999 Aug;162(2):293-306.
(1999)
Abstract
Polascik TJ, Wang ZP, Shue M, Di S, Gurganus RT, Hortopan SC, Ts'o PO, Partin AW. Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells. J Urol. 1999 Sep;162(3 Pt 1):749-52.
(1999)
Abstract
Polascik TJ and Marshall FF: Intracaval tumors, pp 73-77. In: Glenn's Urologic Surgery, fifth edition. Ed. Graham Jr SD. Lippincott-Raven, Philadelphia 1998.
(1998)
Polascik TJ and Partin AW: Multivariate analysis: Predicting pathologic stage of prostate cancer with PSA. Contemporary Urology 10:76-79, 1998.
(1998)
Polascik TJ, Chen RN. Laparoscopic ureteroureterostomy for retrocaval ureter. J Urol. 1998 Jul;160(1):121-2.
(1998)
Abstract
Polascik TJ, Oesterling JE, and Partin AW: Prostate-specific antigen 1998: What we have learned and where we are going. Part I: Clinical utility of PSA for the detetion ofprostate cancer. AUA Update Series, Vol. 17, No. 27, 1998.
(1998)
Polascik TJ, Oesterling JE, and Partin AW: Prostate-specific antigen 1998: What we have learned and where we are going. Part II: Detection, staging and monitoring of prostate cancer. AUA Updat Series, Vol. 17, No. 28, 1998.
(1998)
Polascik TJ, Partin AW, Pound CR, Marshall FF. Frequent occurrence of metastatic disease in patients with renal cell carcinoma and intrahepatic or supradiaphragmatic intracaval extension treated with surgery: an outcome analysis. Urology. 1998 Dec;52(6):995-9.
(1998)
Abstract
Polascik TJ, Pearson JD, Partin AW, Polascik DT. Use of multivariate models to improve prediction of pathologic stage for men with clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 1998 Dec;1(6):301-306.
(1998)
Abstract
Polascik TJ, Pearson JD, Partin AW. Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen. Semin Urol Oncol. 1998 Aug;16(3):160-71.
(1998)
Abstract
Polascik TJ, Pound CR, DeWeese TL, Walsh PC. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology. 1998 Jun;51(6):884-9; discussion 889-90.
(1998)
Abstract
Polascik TJ and Marshall FF: Intraoperative sonographic evaluation of the kidney. AUA Update Series, Vol. XVI, No. 18, 1997.
(1997)
Polascik TJ, Cairns P, Epstein JI, Fuzesi L, Ro JY, Marshall FF, Sidransky D, Schoenberg M. Distal nephron renal tumors: microsatellite allelotype. Cancer Res. 1996 Apr 15;56(8):1892-5.
(1996)
Abstract
Polascik TJ, Chan-Tack KM, Jeffs RD, Gearhart JP. Reappraisal of the role of human chorionic gonadotropin in the diagnosis and treatment of the nonpalpable testis: a 10-year experience. J Urol. 1996 Aug;156(2 Pt 2):804-6.
(1996)
Abstract
Steiner G, Cairns P, Polascik TJ, Marshall FF, Epstein JI, Sidransky D, Schoenberg M. High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. Cancer Res. 1996 Nov 1;56(21):5044-6.
(1996)
Abstract
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995 Oct;11(2):210-2.
(1995)
Abstract
Chang WY, Cairns P, Schoenberg MP, Polascik TJ, Sidransky D. Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Res. 1995 Aug 1;55(15):3246-9.
(1995)
Abstract
Polascik TJ, Cairns P, Chang WY, Schoenberg MP, Sidransky D. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res. 1995 Nov 15;55(22):5396-9.
(1995)
Abstract
Polascik TJ, Meng MV, Epstein JI, Marshall FF. Intraoperative sonography for the evaluation and management of renal tumors: experience with 100 patients. J Urol. 1995 Nov;154(5):1676-80.
(1995)
Abstract
Polascik TJ, Moore RG, Rosenberg MT, Kavoussi LR. Comparison of laparoscopic and open retropubic urethropexy for treatment of stress urinary incontinence. Urology. 1995 Apr;45(4):647-52.
(1995)
Abstract
Polascik TJ, Pound CR, Meng MV, Partin AW, Marshall FF. Partial nephrectomy: technique, complications and pathological findings. J Urol. 1995 Oct;154(4):1312-8.
(1995)
Abstract
Polascik TJ, Walsh PC. Radical retropubic prostatectomy: the influence of accessory pudendal arteries on the recovery of sexual function. J Urol. 1995 Jul;154(1):150-2.
(1995)
Abstract
Riopel MA, Polascik TJ, Partin AW, Sauvageot J, Walsh PC, Epstein JI. Radical prostatectomy in men less than 50 years old. Urol Oncol. 1995 Mar-Apr;1(2):80-3.
(1995)
Abstract
